Human pathology

Home page > A. Molecular pathology > EGFR

EGFR

MIM.131550 7p12.3-p12.1

Pathology

- gene amplification and overexpression

  • glioblastoma (34%)
  • anaplastic oligodendroglioma

- germline mutations

  • non-small cell lung cancer predisposition (16258541)

- somatic mutations

  • non-small cell lung cancers
    • Somatic activating mutations in EGFR identify a subset of non-small cell lung cancer that respond to tyrosine kinase inhibitors.
    • acquisition of drug resistance (somatic EGFR-T790M) (16258541)

EGFR-inhibitors

- gefitinib

Reviews

- Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007 Mar;7(3):169-81. PMID: 17318210

- Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 2006 Nov;6(11):876-85. PMID: 17036041

- Herbst RS, Fukuoka M, Baselga J. Gefitinib?a novel targeted approach to treating cancer. Nat Rev Cancer. 2004 Dec;4(12):956-65. PMID: 15573117

- Carpenter G. The EGF receptor: a nexus for trafficking and signaling. Bioessays. 2000 Aug;22(8):697-707. PMID: 10918300

References

- Hijiya N, Miyawaki M, Kawahara K, Akamine S, Tsuji K, Kadota J, Akizuki S, Uchida T, Matsuura K, Tsukamoto Y, Moriyama M. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Hum Pathol. 2008 Mar;39(3):316-23. PMID: 18261621

- Ch?ng S, Low I, Ng D, Brasch H, Sullivan M, Davis P, Tan ST. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol. 2008 Mar;39(3):344-9. Epub 2007 Nov 28. PMID: 18045646